Personensuche
Personensuche
Es wurde 1 Person gefunden.
Funktionen
-
Assistenzarzt/-ärztin, Klinik für Dermatologie
Aktuelle Veranstaltungen
Vergangene Veranstaltungen (max. 10)
-
SoSe 2025
-
WiSe 2024
-
SoSe 2024
-
WiSe 2023
-
SoSe 2023
-
WiSe 2022
-
SoSe 2022
-
WiSe 2021
-
SoSe 2021
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell CarcinomaIn: European Journal of Cancer (EJC), Jg. 217, 2025, 115254
-
First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma : A multicenter study from the prospective skin cancer registry ADOREGIn: European Journal of Cancer (EJC), Jg. 220, 2025, 115356DOI (Open Access)
-
Survival after cessation of immunotherapies in melanoma : A systematic review and meta-analysisIn: Journal of the European Academy of Dermatology and Venereology, Jg. 39, 2025, Nr. 11, S. 1961 – 1974DOI (Open Access)
-
pTERT mutational status is associated with survival in stage IV melanoma patients receiving first-line immune therapyIn: European Journal of Cancer (EJC), Jg. 220, 2025, 115337DOI (Open Access)
-
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanomaIn: European Journal of Cancer (EJC), Jg. 202, 2024, 113976DOI (Open Access)
-
Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockadeIn: European Journal of Cancer (EJC), Jg. 200, 2024, 113536DOI (Open Access)
-
Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanomaIn: Frontiers in Immunology, Jg. 15, 2024, 1383125DOI (Open Access)
-
Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanomaIn: Science Advances, Jg. 10, 2024, Nr. 48, eadp4670DOI (Open Access)
-
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapyIn: European Journal of Cancer (EJC), Jg. 199, 2024, 113563
-
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomasIn: European Journal of Cancer (EJC), Jg. 208, 2024, 114208DOI (Open Access)
-
Characterisation and outcome of RAC1 mutated melanomaIn: European Journal of Cancer (EJC), Jg. 183, 2023, S. 1 – 10
-
Database for queries of melanoma cohorts with molecular and clinical dataIn: Pigment Cell and Melanoma Research, Jg. 36, 2023, Nr. 2, S. 252 – 258DOI (Open Access)
-
HLA class II loss and JAK1/2 deficiency coevolve in melanoma leading to CD4 T cell and IFNγ cross-resistanceIn: Clinical Cancer Research, Jg. 29, 2023, Nr. 15, S. 2894 – 2907
-
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma : a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREGIn: European Journal of Cancer (EJC), Jg. 188, 2023, S. 140 – 151DOI, Online Volltext (Open Access)
-
TERT expression is associated with metastasis from thin primaries, exhausted CD4+ T cells in melanoma and with DNA repair across cancer entitiesIn: PLoS ONE, Jg. 18, 2023, Nr. 7, e0281487DOI (Open Access)
-
Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responsesIn: Immunity, Jg. 56, 2023, Nr. 6, S. 1341 – 1358.e11DOI (Open Access)
-
Clinical and pathological characteristics of familial melanoma with germline TERT promoter variantsIn: Pigment Cell and Melanoma Research, Jg. 35, 2022, Nr. 6, S. 573 – 586DOI (Open Access)
-
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanomaIn: Journal for ImmunoTherapy of Cancer, Jg. 10, 2022, Nr. 7DOI (Open Access)
-
Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient SurvivalIn: Cancers, Jg. 14, 2022, Nr. 9, 2090DOI, Online Volltext (Open Access)
-
Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic LesionsIn: Cancers, Jg. 14, 2022, Nr. 17, 4066DOI, Online Volltext (Open Access)
-
Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumorsIn: International Journal of Cancer, Jg. 151, 2022, Nr. 9, S. 1542 – 1554DOI (Open Access)
-
Genetic characterization of advanced conjunctival melanoma and response to systemic treatmentIn: European Journal of Cancer (EJC), Jg. 166, 2022, S. 60 – 72
-
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma : An evaluation of the multicenter prospective skin cancer registry ADOREGIn: European Journal of Cancer (EJC), Jg. 167, 2022, S. 32 – 41DOI (Open Access)
-
Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanomaIn: Cancer Imaging, Jg. 22, 2022, Nr. 1DOI, Online Volltext (Open Access)
-
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma : An international, retrospective, cohort studyIn: Annals of Oncology, Jg. 33, 2022, Nr. 9, S. 968 – 980
-
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapyIn: European Journal of Cancer (EJC), Jg. 161, 2022, S. 99 – 107DOI, Online Volltext (Open Access)
-
The Prognostic Relevance of PMCA4 Expression in Melanoma : Gender Specificity and Implications for Immune Checkpoint InhibitionIn: International Journal of Molecular Sciences (IJMS), Jg. 23, 2022, Nr. 6, 3324DOI, Online Volltext (Open Access)
-
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastasesIn: European Journal of Cancer (EJC), Jg. 152, 2021, S. 139 – 154
-
GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular TumorsIn: Frontiers in Genetics, Jg. 12, 2021, 663272DOI, Online Volltext (Open Access)
-
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition : A Descriptive Observational Retrospective Multicenter AnalysisIn: Frontiers in Oncology, Jg. 11, 2021, 765608DOI, Online Volltext (Open Access)
-
Hematological immune related adverse events after treatment with immune checkpoint inhibitorsIn: European Journal of Cancer (EJC), Jg. 147, 2021, S. 170 – 181
-
Leptomeningeal disease from melanoma : Poor prognosis despite new therapeutic modalitiesIn: European Journal of Cancer (EJC), Jg. 148, 2021, S. 395 – 404
-
Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphologyIn: European Journal of Cancer (EJC), Jg. 148, 2021, S. 340 – 347DOI, Online Volltext (Open Access)
-
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsIn: European Journal of Cancer (EJC), Jg. 159, 2021, S. 113 – 124
-
Rare TERT Promoter Mutations Present in Benign and Malignant Cutaneous Vascular TumorsIn: Dermato, Jg. 1, 2021, Nr. 1, S. 18 – 25DOI (Open Access)
-
Response to comment : Molecular pathology as a diagnostic aid in difficult to classify melanocytic tumours with spitzoid morphologyIn: European Journal of Cancer (EJC), Jg. 157, 2021, S. 514 – 515
-
Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete responseIn: European Journal of Cancer (EJC), Jg. 149, 2021, S. 37 – 48DOI (Open Access)
-
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patientsIn: European Journal of Cancer (EJC), Jg. 155, 2021, S. 268 – 280
-
Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade : A Case ReportIn: Frontiers in Oncology, Jg. 10, 2020, S. 592609DOI, Online Volltext (Open Access)
-
Fatal swelling of the groin – Clear cell sarcoma : A rare but important differential diagnosis to malignant melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG), Jg. 18, 2020, Nr. 10, S. 1165 – 1168DOI (Open Access)
-
GNAQ and GNA11 mutant nonuveal melanoma : A subtype distinct from both cutaneous and uveal melanomaIn: British Journal of Dermatology: BJD, Jg. 183, 2020, Nr. 5, S. 928 – 939DOI (Open Access)
-
Immuntherapie beim malignen MelanomIn: Der Internist, Jg. 61, 2020, Nr. 7, S. 669 – 675DOI (Open Access)
-
Malignes Melanom : Stellenwert der BRAF-Inhibition beim malignen MelanomIn: Der Onkologe, Jg. 26, 2020, Nr. 8, S. 713 – 720
-
A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification taskIn: European Journal of Cancer (EJC), Jg. 111, 2019, S. 148 – 154DOI (Open Access)
-
Clinical and genetic analysis of melanomas arising in acral sitesIn: European Journal of Cancer (EJC), Jg. 119, 2019, S. 66 – 76DOI (Open Access)
-
Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification taskIn: European Journal of Cancer (EJC), Jg. 113, 2019, S. 47 – 54DOI (Open Access)
-
Metastatic Merkel cell carcinoma and myasthenia gravis : contraindication for therapy with immune checkpoint inhibitors?In: Journal for ImmunoTherapy of Cancer, Jg. 7, 2019, Nr. 1, S. 141DOI, Online Volltext (Open Access)
-
Pruritus in patients with chronic leg ulcers : a frequent and often neglected problemIn: International Wound Journal (IWJ), Jg. 16, 2019, Nr. 6, S. 1464 – 1470DOI, Online Volltext (Open Access)
-
Evolution of melanoma cross-resistance to CD8⁺ T cells and MAPK inhibition in the course of BRAFi treatmentIn: OncoImmunology, Jg. 7, 2018, Nr. 8, e1450127DOI, Online Volltext (Open Access)
-
Correlation of Laboratory Parameters at the Start of adjuvant Treatment of Stage III Melanoma Patients with clinical Outcome : A multicenter Real World StudyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 22, 2024, Nr. Suppl. 4, S. 8 – 9
-
Deciphering unresectable in-transit metastasis in melanoma : Multi-modal and longitudinal insightsIn: Annals of Oncology. Amsterdam: Elsevier, Jg. 35, 2024, Nr. Suppl. 2, S. S736
-
Molekulare und klinische Charakterisierung von BRAF/NRAS/NF1-wt Melanomen
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 21, 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 21DOI (Open Access) -
Klinische und pathologische Merkmale des familiären Melanoms bei Keimbahn-TERT-Promotorvarianten
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 20, 2022, Nr. S3, S. 6 -
Predictors of long-term survival of stage IV melanoma patients : a multicenter DeCOG study on 539 patients from the prospective skin cancer registry ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 20, 2022, Nr. S3, S. 16 – 17 -
Efficacy of checkpoint inhibitors (CPIs) in acral melanoma (AM)In: Annals of Oncology. Amsterdam: Elsevier, Jg. 32, 2021, Nr. Suppl. 5, S. 876 – S.877DOI (Open Access)
-
Efficacy of checkpoint inhibitors (CPIs) in acral melanoma (AM)
48th Annual Scientific Meeting Cancer care and research: Learning from the past and improving the future, 16-18 November 2021,In: Asia-Pacific Journal of Clinical Oncology: Wiley, Jg. 17, 2021, Nr. 9, SI, S. 64 – 65DOI (Open Access) -
Immune checkpoint-Inhibition in Patients with NRAS-mutated Melanoma compared to Patients with NRAS Wild-type Melanoma : Results of a Study on 702 Patients from the prospective, multicenter Registry ADOREGIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 19, 2021, Nr. Suppl. 4, S. 59 – 60
-
TERT Promoter Mutations associated with longer progression-free and Overall Survival under BRAF/MEK TherapyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 19, 2021, Nr. Suppl. 4, S. 31
-
Auswirkungen der überarbeiteten AJCC‐Klassifikation (8. Edition) auf das Essener Melanomkollektiv
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 16, 2018, Nr. S6, S. 61 – 62DOI (Open Access) -
Autoimmunbedingte Gastritis nach Immuncheckpoint‐Blockade : eine Fallserie
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 16, 2018, Nr. S6, S. 26 – 27DOI (Open Access) -
Clear Cell Sarcoma - a rare Differential Diagnosis of malignant MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 16, 2018, Nr. Suppl. 6, S. 3
-
Evolution of cross‐resistance to CD8+ T cells in the course of BRAF and MEK inhibitor treatment in BRAFV600E melanoma
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 16, 2018, Nr. 6, S. 53DOI (Open Access) -
Klarzellsarkom – eine seltene Differentialdiagnose des malignen Melanoms
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 16, 2018, Nr. S6, S. 3DOI (Open Access) -
Meningeosis melanomatosa : Schlechte Prognose trotz neuer Systemtherapeutika
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 16, 2018, Nr. S6, S. 11 – 12DOI (Open Access) -
Partielle Remission eines fortgeschrittenen Melanoms durch eine Kombinationstherapie mit Nivolumab und Trametinib nach Therapieversagen unter Ipilimumab + Nivolumab
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 16, 2018, Nr. S6, S. 38DOI (Open Access) -
Diagnostik und Therapie der immunvermittelten Thyreoiditis unter Therapie mit Ipilimumab und NivolumabIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 15, 2017, Nr. Suppl. 3, S. 26 – 27
-
Characterization of Vemurafenib- and IFNy-induces senescence-like melanoma phenotypes and their influence on NK and T cell sensitivity of tumor cellsDuisburg ; Essen, 2017
-
Melanom mit unbekanntem Primarius (MUP) - eine monozentrische Auswertung
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 21, 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 76 – 77DOI (Open Access) -
Multi-modal and longitudinal characterization of the tumor and immune microenvironment from primary melanoma to in-transit and distant metastasis
ESMO Congress 2023 ; 20 - 24 October 2023 Madrid, Spain,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 34, 2023, Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S694DOI (Open Access) -
Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses
Joint Conference of the Société Française d'Immunologie (SFI) and the Deutsche Gesellschaft für Immunologie (DGfI) ; 26 - 29 September, 2023, Strasbourg, France,In: European Journal of Immunology. Hoboken: Wiley, Jg. 53, 2023, Nr. S2, Special issue: Abstracts: Joint Conference of the Société Française d'Immunologie (SFI) and the Deutsche Gesellschaft für Immunologie (DGfI), 26–29 September, 2023, Strasbourg, France, S. 152DOI (Open Access) -
Genetic and methylation analysis of CTNNB1 mutations in benign and malignant melanocytic lesions
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 20, 2022, Nr. S3, S. 84 -
MAPKinase Inhibition nach Versagen einer PD-1 basierten Immuncheckpoint Blockade in Patienten:innen mit fortgeschrittenem Melanom : eine Auswertung des multizentrischen prospektiven Hautkrebsregisters ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 20, 2022, Nr. S3, S. 28 -
Molekularpathologie und Methylierungsprofile als diagnostische Unterstützung zur Differenzierung von Klarzellsarkomen und melanozytären Tumoren
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 20, 2022, Nr. S3, S. 88 -
Outcomes of patients with resected stage III/IV acral or mucosal melanoma treated with adjuvant anti-PD-1 therapy
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 33, 2022, Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S915 – S916DOI (Open Access) -
Patterns of response/progression and management following progressive disease (PD) with anti-PD-(L)1 (PD(L)1) in patients (pts) with advanced Merkel cell carcinoma (MCC)
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 33, 2022, Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S924 – S925DOI (Open Access) -
Additional Benefit of FDG-PET when Discontinuing Immune Checkpoint Inhibitor Therapy in Patients with metastatic Melanoma
31. Deutscher Hautkrebskongress (ADO-Jahrestagung), 8.–11. September 2021, Hamburg, Germany and Virtual,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 19, 2021, Nr. Suppl. 4, S. 75 – 76DOI (Open Access)